Untapping the Potential of Astragaloside IV in the Battle Against Respiratory Diseases

References

• Li X, Cao X, Guo M, et al. Trends and risk factors of mortality and disability adjusted life years for chronic respiratory diseases from 1990 to 2017: systematic analysis for the Global Burden of Disease Study 2017. BMJ. 2020;368:m234. doi:10.1136/bmj.m234
   PubMed Web of Science ®Google Scholar
• GBD Chronic Respiratory Disease Collaborators. Prevalence and attributable health burden of chronic respiratory diseases, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir Med. 2020;8(6):585–596. doi:10.1016/S2213-2600(20)30105-3
   PubMed Web of Science ®Google Scholar
• Liu Y, Tong C, Tang Y, et al. Tanshinone IIA alleviates blast-induced inflammation, oxidative stress and apoptosis in mice partly by inhibiting the PI3K/Akt/FoxO1 signaling pathway. Free Radic Biol Med. 2020;152:52–60. doi:10.1016/j.freeradbiomed.2020.02.032
   PubMed Web of Science ®Google Scholar
• Huang B, Hao M, Li C, et al. Acetyltanshinone IIA reduces the synthesis of cell cycle-related proteins by degrading p70S6K and subsequently inhibits drug-resistant lung cancer cell growth. Pharmacol Res. 2022;179:106209. doi:10.1016/j.phrs.2022.106209
   PubMed Web of Science ®Google Scholar
• Li H, Wu M, Guo C, et al. Tanshinone IIA regulates Keap1/Nrf2 signal pathway by activating sestrin2 to restrain pulmonary fibrosis. Am J Chin Med. 2022;50(8):2125–2151. doi:10.1142/S0192415X22500914
   PubMed Web of Science ®Google Scholar
• Li L, Dong P, Hou C, et al. Hydroxysafflor yellow A (HSYA) attenuates hypoxic pulmonary arterial remodelling and reverses right ventricular hypertrophy in rats. J Ethnopharmacol. 2016;186:224–233. doi:10.1016/j.jep.2016.04.004
   PubMed Web of Science ®Google Scholar
• Li C, Zhu H, Zhang S, et al. Astragaloside IV ameliorates pulmonary vascular remodeling in hypoxia-induced pulmonary hypertension by restraining the T follicular helper cell response and expanding T follicular regulatory cell response. Phytomedicine. 2022;102:154171. doi:10.1016/j.phymed.2022.154171
   PubMed Web of Science ®Google Scholar
• Lee MK, Kim HD, Lee SH, et al. Curcumin ameliorates particulate matter-induced pulmonary injury through bimodal regulation of macrophage inflammation via NF-κB and Nrf2. Int J Mol Sci. 2023;24(3):1858. doi:10.3390/ijms24031858
   PubMed Web of Science ®Google Scholar
• Chuang HM, Ho LI, Huang MH, et al. Non-canonical regulation of type I collagen through promoter binding of SOX2 and its contribution to ameliorating pulmonary fibrosis by butylidenephthalide. Int J Mol Sci. 2018;19(10):3024. doi:10.3390/ijms19103024
   PubMed Web of Science ®Google Scholar
• Que H, Hong W, Lan T, et al. Tripterin liposome relieves severe acute respiratory syndrome as a potent COVID-19 treatment. Signal Transduct Target Ther. 2022;7(1):399. doi:10.1038/s41392-022-01283-6
   PubMed Web of Science ®Google Scholar
• Li C, Han P, Mao H, et al. Glycyrrhizic acid-based carbonized dots boost antiviral activity against influenza A virus via multisite inhibition mechanisms. ACS Appl Mater Interfaces. 2023. doi:10.1021/acsami.2c21319
   Web of Science ®Google Scholar
• Zhang P, Zhang Y, Wang L, et al. Reversal of NADPH oxidase-dependent early oxidative and inflammatory responses in chronic obstructive pulmonary disease by puerarin. Oxid Med Cell Longev. 2022;2022:5595781. doi:10.1155/2022/5595781
   PubMed Web of Science ®Google Scholar
• Teng C, Li B, Lin C, et al. Targeted delivery of baicalein-p53 complex to smooth muscle cells reverses pulmonary hypertension. J Control Release. 2022;341:591–604. doi:10.1016/j.jconrel.2021.12.006
   PubMed Web of Science ®Google Scholar
• Li X, Wang X, Han C, et al. Astragaloside IV suppresses collagen production of activated hepatic stellate cells via oxidative stress-mediated p38 MAPK pathway. Free Radic Biol Med. 2013;60:168–176. doi:10.1016/j.freeradbiomed.2013.02.027
   PubMed Web of Science ®Google Scholar
• Song MT, Ruan J, Zhang RY, et al. Astragaloside IV ameliorates neuroinflammation-induced depressive-like behaviors in mice via the PPARγ/NF-κB/NLRP3 inflammasome axis. Acta Pharmacol Sin. 2018;39(10):1559–1570. doi:10.1038/aps.2017.208
   PubMed Web of Science ®Google Scholar
• Lu J, Wang QY, Zhou Y, et al. Astragaloside IV against cardiac fibrosis by inhibiting TRPM7 channel. Phytomedicine. 2017;30:10–17. doi:10.1016/j.phymed.2017.04.002
   PubMed Web of Science ®Google Scholar
• Zheng Y, Dai Y, Liu W, et al. Astragaloside IV enhances taxol chemosensitivity of breast cancer via caveolin-1-targeting oxidant damage. J Cell Physiol. 2019;234(4):4277–4290. doi:10.1002/jcp.27196
   PubMed Web of Science ®Google Scholar
• Yu SY, Ouyang HT, Yang JY, et al. Subchronic toxicity studies of Radix astragali extract in rats and dogs. J Ethnopharmacol. 2007;110(2):352–355. doi:10.1016/j.jep.2006.09.024
   PubMed Web of Science ®Google Scholar
• Kang X, Su S, Hong W, et al. Research progress on the ability of astragaloside IV to protect the brain against ischemia-reperfusion injury. Front Neurosci. 2021;15:755902. doi:10.3389/fnins.2021.755902
   PubMed Web of Science ®Google Scholar
• Hl W, Qh Z, Mb X, et al. Astragaloside IV for experimental focal cerebral ischemia: preclinical evidence and possible mechanisms. Oxid Med Cell Longev. 2017;2017. doi:10.1155/2017/8424326
   Web of Science ®Google Scholar
• Zhang Y, Du M, Wang J, et al. Astragaloside IV relieves atherosclerosis and hepatic steatosis via MAPK/NF-κB signaling pathway in LDLR−/− mice. Front Pharmacol. 2022;13:828161. doi:10.3389/fphar.2022.828161
   PubMed Web of Science ®Google Scholar
• Chen T, Yang P, Jia Y. Molecular mechanisms of astragaloside‑IV in cancer therapy (Review). Int J Mol Med. 2021;47(3):13. doi:10.3892/ijmm.2021.4846
   PubMed Web of Science ®Google Scholar
• Meiqian Z, Leying Z, Chang C. Astragaloside IV inhibits cigarette smoke-induced pulmonary inflammation in mice. Inflammation. 2018;41(5):1671–1680. doi:10.1007/s10753-018-0811-x
   PubMed Web of Science ®Google Scholar
• Yang X, Wang F. The effect of astragaloside IV on JAK2-STAT6 signalling pathway in mouse model of ovalbumin-induced asthma. J Anim Physiol Anim Nutr (Berl). 2019;103(5):1578–1584. doi:10.1111/jpn.13114
   PubMed Web of Science ®Google Scholar
• Li L, Li G, Chen M, et al. Astragaloside IV enhances the sensibility of lung adenocarcinoma cells to bevacizumab by inhibiting autophagy. Drug Dev Res. 2022;83(2):461–469. doi:10.1002/ddr.21878
   PubMed Web of Science ®Google Scholar
• Gong F, Qu R, Li Y, et al. Astragalus mongholicus: a review of its anti-fibrosis properties. Front Pharmacol. 2022;13:976561. doi:10.3389/fphar.2022.976561
   PubMed Web of Science ®Google Scholar
• Wang X, Wang Y, Huang D, et al. Astragaloside IV regulates the ferroptosis signaling pathway via the Nrf2/SLC7A11/GPX4 axis to inhibit PM2.5-mediated lung injury in mice. Int Immunopharmacol. 2022;112:109186. doi:10.1016/j.intimp.2022.109186
   PubMed Web of Science ®Google Scholar
• Poch D, Mandel J. Pulmonary hypertension. Ann Intern Med. 2021;174(4):ITC49–ITC64. doi:10.7326/AITC202104200
   PubMed Web of Science ®Google Scholar
• Weatherald J, Boucly A, Peters A, et al. The evolving landscape of pulmonary arterial hypertension clinical trials. Lancet. 2022;400(10366):1884–1898. doi:10.1016/S0140-6736(22)01601-4
   PubMed Web of Science ®Google Scholar
• Xue Z, Li Y, Zhou M, et al. Traditional herbal medicine discovery for the treatment and prevention of pulmonary arterial hypertension. Front Pharmacol. 2021;12:720873. doi:10.3389/fphar.2021.720873
   PubMed Web of Science ®Google Scholar
• Zhang X, Chen J, Xu P, et al. Protective effects of astragaloside IV against hypoxic pulmonary hypertension. Medchemcomm. 2018;9(10):1715–1721. doi:10.1039/c8md00341f
   PubMed Web of Science ®Google Scholar
• Thenappan T, Ormiston ML, Ryan JJ, et al. Pulmonary arterial hypertension: pathogenesis and clinical management. BMJ. 2018;360:j5492. doi:10.1136/bmj.j5492
   PubMed Web of Science ®Google Scholar
• Bodas M, Subramaniyan B, Karmouty-Quintana H, et al. The emerging role of NOTCH3 receptor signalling in human lung diseases. Expert Rev Mol Med. 2022;24:e33. doi:10.1017/erm.2022.27
   PubMed Web of Science ®Google Scholar
• Zhang Y, Hernandez M, Gower J, et al. JAGGED-NOTCH3 signaling in vascular remodeling in pulmonary arterial hypertension. Sci Transl Med. 2022;14(643):eabl5471. doi:10.1126/scitranslmed.abl5471
   PubMed Web of Science ®Google Scholar
• Yao J, Fang X, Zhang C, et al. Astragaloside IV attenuates hypoxia‑induced pulmonary vascular remodeling via the Notch signaling pathway. Mol Med Rep. 2021;23(1):89. doi:10.3892/mmr.2020.11726
   PubMed Web of Science ®Google Scholar
• Tian X, Zhang X, Feng Y, et al. Astragaloside IV in hypoxic pulmonary hypertension: an in vivo and in vitro experiments. Appl Biochem Biotechnol. 2022;194(12):6319–6334. doi:10.1007/s12010-022-04027-y
   PubMed Web of Science ®Google Scholar
• Lee S, Suh GY, Ryter SW, et al. Regulation and function of the nucleotide binding domain leucine-rich repeat-containing receptor, pyrin domain-containing-3 inflammasome in lung disease. Am J Respir Cell Mol Biol. 2016;54(2):151–160. doi:10.1165/rcmb.2015-0231TR
   PubMed Web of Science ®Google Scholar
• Sun Y, Lu M, Sun T, et al. Astragaloside IV attenuates inflammatory response mediated by NLRP-3/calpain-1 is involved in the development of pulmonary hypertension. J Cell Mol Med. 2021;25(1):586–590. doi:10.1111/jcmm.15671
   PubMed Web of Science ®Google Scholar
• Richeldi L, Collard HR, Jones MG. Idiopathic pulmonary fibrosis. Lancet. 2017;389(10082):1941–1952. doi:10.1016/S0140-6736(17)30866-8
   PubMed Web of Science ®Google Scholar
• Mackinnon AC, Gibbons MA, Farnworth SL, et al. Regulation of transforming growth factor-β1-driven lung fibrosis by galectin-3. Am J Respir Crit Care Med. 2012;185(5):537–546. doi:10.1164/rccm.201106-0965OC
   PubMed Web of Science ®Google Scholar
• Qian W, Cai X, Qian Q, et al. Astragaloside IV modulates TGF-β1-dependent epithelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis. J Cell Mol Med. 2018;22(9):4354–4365. doi:10.1111/jcmm.13725
   PubMed Web of Science ®Google Scholar
• Qian W, Cai X, Qian Q, et al. Metastasis-associated protein 1 promotes epithelial-mesenchymal transition in idiopathic pulmonary fibrosis by up-regulating Snail expression. J Cell Mol Med. 2020;24(11):5998–6007. doi:10.1111/jcmm.15062
   PubMed Web of Science ®Google Scholar
• Tian R, Zhu Y, Yao J, et al. NLRP3 participates in the regulation of EMT in bleomycin-induced pulmonary fibrosis. Exp Cell Res. 2017;357(2):328–334. doi:10.1016/j.yexcr.2017.05.028
   PubMed Web of Science ®Google Scholar
• Hou Y, Zhen Y, Xue Q, et al. Astragaloside IV attenuates TGF-β-mediated epithelial-mesenchymal transition of pulmonary fibrosis via suppressing NLRP3 expression in vitro. Pharmazie. 2021;76(2):97–102. doi:10.1691/ph.2021.0933
   PubMed Web of Science ®Google Scholar
• Wang E, Wang L, Ding R, et al. Astragaloside IV acts through multi-scale mechanisms to effectively reduce diabetic nephropathy. Pharmacol Res. 2020;157:104831. doi:10.1016/j.phrs.2020.104831
   PubMed Web of Science ®Google Scholar
• Yu X, Xiao Q, Yu X, et al. A network pharmacology-based study on the mechanism of astragaloside IV alleviating renal fibrosis through the AKT1/GSK-3β pathway. J Ethnopharmacol. 2022;297:115535. doi:10.1016/j.jep.2022.115535
   PubMed Web of Science ®Google Scholar
• Zhu J, Wen K. Astragaloside IV inhibits TGF-β1-induced epithelial-mesenchymal transition through inhibition of the PI3K/Akt/NF-κB pathway in gastric cancer cells. Phytother Res. 2018;32(7):1289–1296. doi:10.1002/ptr.6057
   PubMed Web of Science ®Google Scholar
• Yu WN, Sun LF, Yang H. Inhibitory effects of astragaloside IV on bleomycin-induced pulmonary fibrosis in rats via attenuation of oxidative stress and inflammation. Inflammation. 2016;39(5):1835–1841. doi:10.1007/s10753-016-0420-5
   PubMed Web of Science ®Google Scholar
• Tong J, Wu Z, Wang Y, et al. Astragaloside IV synergizing with ferulic acid ameliorates pulmonary fibrosis by TGF-β1/Smad3 signaling. Evid Based Complement Alternat Med. 2021;2021:8845798. doi:10.1155/2021/8845798
   PubMed Web of Science ®Google Scholar
• Li N, Feng F, Wu K, et al. Inhibitory effects of astragaloside IV on silica-induced pulmonary fibrosis via inactivating TGF-β1/Smad3 signaling. Biomed Pharmacother. 2019;119:109387. doi:10.1016/j.biopha.2019.109387
   PubMed Web of Science ®Google Scholar
• Li LC, Xu L, Hu Y, et al. Astragaloside IV improves bleomycin-induced pulmonary fibrosis in rats by attenuating extracellular matrix deposition. Front Pharmacol. 2017;8:513. doi:10.3389/fphar.2017.00513
   PubMed Web of Science ®Google Scholar
• Zhang J, Wu C, Gao L, et al. Astragaloside IV derived from Astragalus membranaceus: a research review on the pharmacological effects. Adv Pharmacol. 2020;87:89–112. doi:10.1016/bs.apha.2019.08.002
   PubMedGoogle Scholar
• Pitt JM, Marabelle A, Eggermont A, et al. Targeting the tumor microenvironment: removing obstruction to anticancer immune responses and immunotherapy. Ann Oncol. 2016;27(8):1482–1492. doi:10.1093/annonc/mdw168
   PubMed Web of Science ®Google Scholar
• Otano I, Ucero AC, Zugazagoitia J, et al. At the crossroads of immunotherapy for oncogene-addicted subsets of NSCLC. Nat Rev Clin Oncol. 2023;20(3):143–159. doi:10.1038/s41571-022-00718-x
   PubMed Web of Science ®Google Scholar
• Wang S, Rong R, Yang DM, et al. Features of tumor-microenvironment images predict targeted therapy survival benefit in patients with EGFR-mutant lung cancer. J Clin Invest. 2023;133(2):e160330. doi:10.1172/JCI160330
   PubMed Web of Science ®Google Scholar
• Smith C, Chang MY, Parker KH, et al. IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov. 2012;2(8):722–735. doi:10.1158/2159-8290.CD-12-0014
   PubMed Web of Science ®Google Scholar
• Wang K, Ye K, Zhang X, et al. Dual nicotinamide phosphoribosyltransferase (NAMPT) and indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors for the treatment of drug-resistant nonsmall-cell lung cancer. J Med Chem. 2023;66(1):1027–1047. doi:10.1021/acs.jmedchem.2c01954
   PubMed Web of Science ®Google Scholar
• Zhang A, Zheng Y, Que Z, et al. Astragaloside IV inhibits progression of lung cancer by mediating immune function of Tregs and CTLs by interfering with IDO. J Cancer Res Clin Oncol. 2014;140(11):1883–1890. doi:10.1007/s00432-014-1744-x
   PubMed Web of Science ®Google Scholar
• Meng Y, Wang W, Chen M, et al. GBP1 facilitates indoleamine 2,3-dioxygenase extracellular secretion to promote the malignant progression of lung cancer. Front Immunol. 2020;11:622467. doi:10.3389/fimmu.2020.622467
   PubMed Web of Science ®Google Scholar
• Xiang X, Wang J, Lu D, et al. Targeting tumor-associated macrophages to synergize tumor immunotherapy. Signal Transduct Target Ther. 2021;6(1):75. doi:10.1038/s41392-021-00484-9
   PubMed Web of Science ®Google Scholar
• Iglesias-Escudero M, Arias-González N, Martínez-Cáceres E. Regulatory cells and the effect of cancer immunotherapy. Mol Cancer. 2023;22(1):26. doi:10.1186/s12943-023-01714-0
   PubMed Web of Science ®Google Scholar
• Liu PS, Chen YT, Li X, et al. CD40 signal rewires fatty acid and glutamine metabolism for stimulating macrophage anti-tumorigenic functions. Nat Immunol. 2023;24(3):452–462. doi:10.1038/s41590-023-01430-3
   PubMed Web of Science ®Google Scholar
• Xu F, Cui WQ, Wei Y, et al. Astragaloside IV inhibits lung cancer progression and metastasis by modulating macrophage polarization through AMPK signaling. J Exp Clin Cancer Res. 2018;37(1):207. doi:10.1186/s13046-018-0878-0
   PubMed Web of Science ®Google Scholar
• Cheng X, Gu J, Zhang M, et al. Astragaloside IV inhibits migration and invasion in human lung cancer A549 cells via regulating PKC-α-ERK1/2-NF-κB pathway. Int Immunopharmacol. 2014;23(1):304–313. doi:10.1016/j.intimp.2014.08.027
   PubMed Web of Science ®Google Scholar
• Jia L, Lv D, Zhang S, et al. Astragaloside IV inhibits the progression of non-small cell lung cancer through the Akt/GSK-3β/β-Catenin pathway. Oncol Res. 2019;27(4):503–508. doi:10.3727/096504018X15344989701565
   PubMed Web of Science ®Google Scholar
• Li J, Wang Y, Song Y, et al. miR-27a regulates cisplatin resistance and metastasis by targeting RKIP in human lung adenocarcinoma cells. Mol Cancer. 2014;13:193. doi:10.1186/1476-4598-13-193
   PubMed Web of Science ®Google Scholar
• Moro M, Caiola E, Ganzinelli M, et al. Metformin enhances cisplatin-induced apoptosis and prevents resistance to cisplatin in co-mutated KRAS/LKB1 NSCLC. J Thorac Oncol. 2018;13(11):1692–1704. doi:10.1016/j.jtho.2018.07.102
   PubMed Web of Science ®Google Scholar
• Rampioni Vinciguerra GL, Capece M, Distefano R, et al. Role of the miR-301a/Fra-2/GLIPR1 axis in lung cancer cisplatin resistance. Signal Transduct Target Ther. 2023;8(1):37. doi:10.1038/s41392-022-01228-z
   PubMed Web of Science ®Google Scholar
• Zhu C, Xie Y, Li Q, et al. CPSF6-mediated XBP1 3’UTR shortening attenuates cisplatin-induced ER stress and elevates chemo-resistance in lung adenocarcinoma. Drug Resist Updat. 2023;68:100933. doi:10.1016/j.drup.2023.100933
   PubMed Web of Science ®Google Scholar
• Lai ST, Wang Y, Peng F. Astragaloside IV sensitizes non-small cell lung cancer cells to cisplatin by suppressing endoplasmic reticulum stress and autophagy. J Thorac Dis. 2020;12(7):3715–3724. doi:10.21037/jtd-20-2098
   PubMed Web of Science ®Google Scholar
• He CS, Liu YC, Xu ZP, et al. Astragaloside IV enhances cisplatin chemosensitivity in non-small cell lung cancer cells through inhibition of B7-H3. Cell Physiol Biochem. 2016;40(5):1221–1229. doi:10.1159/000453175
   PubMedGoogle Scholar
• Rotow J, Bivona TG. Understanding and targeting resistance mechanisms in NSCLC. Nat Rev Cancer. 2017;17(11):637–658. doi:10.1038/nrc.2017.84
   PubMed Web of Science ®Google Scholar
• Dai PC, Liu DL, Zhang L, et al. Astragaloside IV sensitizes non-small cell lung cancer cells to gefitinib potentially via regulation of SIRT6. Tumour Biol. 2017;39(4):1010428317697555. doi:10.1177/1010428317697555
   Google Scholar
• Xu X, Wang H, Liu S, et al. TP53-dependent autophagy links the ATR-CHEK1 axis activation to proinflammatory VEGFA production in human bronchial epithelial cells exposed to fine particulate matter (PM2.5). Autophagy. 2016;12(10):1832–1848. doi:10.1080/15548627.2016.1204496
   PubMed Web of Science ®Google Scholar
• Li D, Li Y, Li G, et al. Fluorescent reconstitution on deposition of PM2.5 in lung and extrapulmonary organs. Proc Natl Acad Sci U S A. 2019;116(7):2488–2493. doi:10.1073/pnas.1818134116
   PubMed Web of Science ®Google Scholar
• Guohua F, Tieyuan Z, Xinping M, et al. Melatonin protects against PM2.5-induced lung injury by inhibiting ferroptosis of lung epithelial cells in a Nrf2-dependent manner. Ecotoxicol Environ Saf. 2021;223:112588. doi:10.1016/j.ecoenv.2021.112588
   PubMed Web of Science ®Google Scholar
• Xiong R, Jiang W, Li N, et al. PM2.5-induced lung injury is attenuated in macrophage-specific NLRP3 deficient mice. Ecotoxicol Environ Saf. 2021;221:112433. doi:10.1016/j.ecoenv.2021.112433
   PubMed Web of Science ®Google Scholar
• Li Y, Fu S, Li E, et al. Modulation of autophagy in the protective effect of resveratrol on PM2.5-induced pulmonary oxidative injury in mice. Phytother Res. 2018;32(12):2480–2486. doi:10.1002/ptr.6187
   PubMed Web of Science ®Google Scholar
• D J, G N, Km R. Autophagy and autophagy-related pathways in cancer. Nat Rev Mol Cell Biol. 2023. doi:10.1038/s41580-023-00585-z
   Web of Science ®Google Scholar
• Racanelli AC, Kikkers SA, Choi AMK, et al. Autophagy and inflammation in chronic respiratory disease. Autophagy. 2018;14(2):221–232. doi:10.1080/15548627.2017.1389823
   PubMed Web of Science ®Google Scholar
• Pei C, Wang F, Huang D, et al. Astragaloside IV protects from PM2.5-induced lung injury by regulating autophagy via inhibition of PI3K/Akt/mTOR signaling in vivo and in vitro. J Inflamm Res. 2021;14:4707–4721. doi:10.2147/JIR.S312167
   PubMed Web of Science ®Google Scholar
• Wang Z, Wu Y, Pei C, et al. Astragaloside IV pre-treatment attenuates PM2.5-induced lung injury in rats: impact on autophagy, apoptosis and inflammation. Phytomedicine. 2022;96:153912. doi:10.1016/j.phymed.2021.153912
   PubMed Web of Science ®Google Scholar
• Zhao J, Jia Y, Mahmut D, et al. Human hematopoietic stem cell vulnerability to ferroptosis. Cell. 2023;186(4):732–747.e16. doi:10.1016/j.cell.2023.01.020
   PubMed Web of Science ®Google Scholar
• Xia H, Wu Y, Zhao J, et al. N6-Methyladenosine-modified circSAV1 triggers ferroptosis in COPD through recruiting YTHDF1 to facilitate the translation of IREB2. Cell Death Differ. 2023. doi:10.1038/s41418-023-01138-9
   Web of Science ®Google Scholar
• Hu P, Xu Y, Jiang Y, et al. The mechanism of the imbalance between proliferation and ferroptosis in pulmonary artery smooth muscle cells based on the activation of SLC7A11. Eur J Pharmacol. 2022;928:175093. doi:10.1016/j.ejphar.2022.175093
   PubMed Web of Science ®Google Scholar
• Shi X, Li C, Cheng L, et al. Mycobacterium tuberculosis Rv1324 Protein Contributes to Mycobacterial Persistence and Causes Pathological Lung Injury in Mice by Inducing Ferroptosis. Microbiol Spectr. 2023;11(1):e0252622. doi:10.1128/spectrum.02526-22
   PubMed Web of Science ®Google Scholar
• Privitera G, Rana N, Armuzzi A, et al. The gasdermin protein family: emerging roles in gastrointestinal health and disease. Nat Rev Gastroenterol Hepatol. 2023. doi:10.1038/s41575-023-00743-w
   PubMed Web of Science ®Google Scholar
• Huang D, Shi S, Wang Y, et al. Astragaloside IV alleviates PM2.5-caused lung toxicity by inhibiting inflammasome-mediated pyroptosis via NLRP3/caspase-1 axis inhibition in mice. Biomed Pharmacother. 2022;150:112978. doi:10.1016/j.biopha.2022.112978
   PubMed Web of Science ®Google Scholar
• Wu Y, Xiao W, Pei C, et al. Astragaloside IV alleviates PM2.5-induced lung injury in rats by modulating TLR4/MyD88/NF-κB signalling pathway. Int Immunopharmacol. 2021;91:107290. doi:10.1016/j.intimp.2020.107290
   PubMed Web of Science ®Google Scholar
• Chen T, Wang R, Jiang W, et al. Protective effect of astragaloside IV against paraquat-induced lung injury in mice by suppressing Rho signaling. Inflammation. 2016;39(1):483–492. doi:10.1007/s10753-015-0272-4
   PubMed Web of Science ®Google Scholar
• Li H, Yao C, Shi K, et al. Astragaloside IV attenuates hypoxia/reoxygenation injury-induced apoptosis of type II alveolar epithelial cells through miR-21-5p. Bioengineered. 2021;12(1):7747–7754. doi:10.1080/21655979.2021.1982845
   PubMed Web of Science ®Google Scholar
• Xiong P, Jiang LZ, Liao XQ. 黄芪甲苷保护大鼠肺缺血再灌注肺损伤的形态学研究 [Morphological investigation of the protective effect of astragaloside preconditioning against ischemia-reperfusion lung injury in rats]. Nan Fang Yi Ke Da Xue Xue Bao. 2010;30(8):1864–1867.
   PubMedGoogle Scholar
• Georas SN, Wright RJ, Ivanova A, et al. The Precision Interventions for Severe and/or Exacerbation-Prone (PrecISE) Asthma Network: an overview of Network organization, procedures, and interventions. J Allergy Clin Immunol. 2022;149(2):488–516.e9. doi:10.1016/j.jaci.2021.10.035
   PubMed Web of Science ®Google Scholar
• Huang X, Tang L, Wang F, et al. Astragaloside IV attenuates allergic inflammation by regulation Th1/Th2 cytokine and enhancement CD4(+)CD25(+)Foxp3 T cells in ovalbumin-induced asthma. Immunobiology. 2014;219(7):565–571. doi:10.1016/j.imbio.2014.03.005
   PubMed Web of Science ®Google Scholar
• Chen JK, Guo MK, Bai XH, et al. Astragaloside IV ameliorates intermittent hypoxia-induced inflammatory dysfunction by suppressing MAPK/NF-κB signalling pathways in Beas-2B cells. Sleep Breath. 2020;24(3):1237–1245. doi:10.1007/s11325-019-01947-8
   PubMed Web of Science ®Google Scholar
• Jin H, Wang L, Li B, et al. Astragaloside IV ameliorates airway inflammation in an established murine model of asthma by inhibiting the mTORC1 signaling pathway. Evid Based Complement Alternat Med. 2017;2017:4037086. doi:10.1155/2017/4037086
   PubMed Web of Science ®Google Scholar
• Du Q, Chen Z, Zhou LF, et al. Inhibitory effects of astragaloside IV on ovalbumin-induced chronic experimental asthma. Can J Physiol Pharmacol. 2008;86(7):449–457. doi:10.1139/y08-053
   PubMed Web of Science ®Google Scholar
• Gu X, Jiang D, Wang Y, et al. Effects of astragaloside IV on eosinophil activation induced by house dust mite allergen. Mol Med Rep. 2012;6(1):115–120. doi:10.3892/mmr.2012.869
   PubMed Web of Science ®Google Scholar
• Christenson SA, Smith BM, Bafadhel M, et al. Chronic obstructive pulmonary disease. Lancet. 2022;399(10342):2227–2242. doi:10.1016/S0140-6736(22)00470-6
   PubMed Web of Science ®Google Scholar
• Wang L, Gu W, Shi Y, et al. Protective effects of astragaloside IV on IL-8-treated diaphragmatic muscle cells. Exp Ther Med. 2019;17(1):519–524. doi:10.3892/etm.2018.6940
   PubMed Web of Science ®Google Scholar
• Yang IA, Jenkins CR, Salvi SS. Chronic obstructive pulmonary disease in never-smokers: risk factors, pathogenesis, and implications for prevention and treatment. Lancet Respir Med. 2022;10(5):497–511. doi:10.1016/S2213-2600(21)00506-3
   PubMed Web of Science ®Google Scholar
• Chen L, Sun BB, Wang T, et al. Cigarette smoke enhances {beta}-defensin 2 expression in rat airways via nuclear factor-{kappa}B activation. Eur Respir J. 2010;36(3):638–645. doi:10.1183/09031936.00029409
   PubMed Web of Science ®Google Scholar
• Ye Q, Wang B, Mao J. The pathogenesis and treatment of the `Cytokine Storm’ in COVID-19. J Infect. 2020;80(6):607–613. doi:10.1016/j.jinf.2020.03.037
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506. doi:10.1016/S0140-6736(20)30183-5
   PubMed Web of Science ®Google Scholar
• Ge C, He Y. In silico prediction of molecular targets of astragaloside IV for alleviation of COVID-19 hyperinflammation by systems network pharmacology and bioinformatic Gene Expression Analysis. Front Pharmacol. 2020;11:556984. doi:10.3389/fphar.2020.556984
   PubMed Web of Science ®Google Scholar
• Ye M, Luo G, Ye D, et al. Network pharmacology, molecular docking integrated surface plasmon resonance technology reveals the mechanism of Toujie Quwen Granules against coronavirus disease 2019 pneumonia. Phytomedicine. 2021;85:153401. doi:10.1016/j.phymed.2020.153401
   PubMed Web of Science ®Google Scholar
• Gu Y, Wang G, Pan G, et al. Transport and bioavailability studies of astragaloside IV, an active ingredient in Radix astragali. Basic Clin Pharmacol Toxicol. 2004;95(6):295–298. doi:10.1111/j.1742-7843.2004.t01-1-pto950508.x
   PubMed Web of Science ®Google Scholar
• Zhang Q, Zhu LL, Chen GG, et al. Pharmacokinetics of astragaloside iv in beagle dogs. Eur J Drug Metab Pharmacokinet. 2007;32(2):75–79. doi:10.1007/BF03190995
   PubMed Web of Science ®Google Scholar
• Jiangbo Z, Xuying W, Yuping Z, et al. Effect of astragaloside IV on the embryo-fetal development of Sprague-Dawley rats and New Zealand White rabbits. J Appl Toxicol. 2009;29(5):381–385. doi:10.1002/jat.1422
   PubMed Web of Science ®Google Scholar
• Kuo YC, Chen IY, Rajesh R. Astragaloside IV- and nesfatin-1-encapsulated phosphatidylserine liposomes conjugated with wheat germ agglutinin and leptin to activate anti-apoptotic pathway and block phosphorylated tau protein expression for Parkinson’s disease treatment. Mater Sci Eng C Mater Biol Appl. 2021;129:112361. doi:10.1016/j.msec.2021.112361
   PubMed Web of Science ®Google Scholar
• Zhou J, Zhang J, Gao G, et al. Boiling licorice produces self-assembled protein nanoparticles: a novel source of bioactive nanomaterials. J Agric Food Chem. 2019;67(33):9354–9361. doi:10.1021/acs.jafc.9b03208
   PubMed Web of Science ®Google Scholar
• Sun R, Zhang A, Ge Y, et al. Ultra-small-size astragaloside-IV loaded lipid nanocapsules eye drops for the effective management of dry age-related macular degeneration. Expert Opin Drug Deliv. 2020;17(9):1305–1320. doi:10.1080/17425247.2020.1783236
   PubMed Web of Science ®Google Scholar
• Zhang Y, Tao C, Xuan C, et al. Transcriptomic analysis reveals the protection of astragaloside IV against diabetic nephropathy by modulating inflammation. Oxid Med Cell Longev. 2020;2020:9542165. doi:10.1155/2020/9542165
   PubMed Web of Science ®Google Scholar
• Wang M, Shi Y, Yao L, et al. Identification of hub genes in protective effect of astragaloside IV on aconitine-induced cardiac damage in zebrafish based on bioinformatics analysis. Front Pharmacol. 2020;11:957. doi:10.3389/fphar.2020.00957
   PubMed Web of Science ®Google Scholar
• Xia C, He Z, Cai Y. Quantitative proteomics analysis of differentially expressed proteins induced by astragaloside IV in cervical cancer cell invasion. Cell Mol Biol Lett. 2020;25:25. doi:10.1186/s11658-020-00218-9
   PubMed Web of Science ®Google Scholar
• Xu M, Yin J, Xie L, et al. Pharmacokinetics and tolerance of toal astragalosides after intravenous infusion of astragalosides injection in healthy Chinese volunteers. Phytomedicine. 2013;20(12):1105–1111. doi:10.1016/j.phymed.2013.05.004
   PubMed Web of Science ®Google Scholar
• Meng LQ, Tang JW, Wang Y, et al. Astragaloside IV synergizes with ferulic acid to inhibit renal tubulointerstitial fibrosis in rats with obstructive nephropathy. Br J Pharmacol. 2011;162(8):1805–1818. doi:10.1111/j.1476-5381.2011.01206.x
   PubMed Web of Science ®Google Scholar
• Sun B, Rui R, Pan H, et al. Effect of combined use of astragaloside IV (AsIV) and atorvastatin (AV) on expression of PPAR-γ and inflammation-associated cytokines in atherosclerosis rats. Med Sci Monit. 2018;24:6229–6236. doi:10.12659/MSM.908480
   PubMed Web of Science ®Google Scholar
• Wang D, Liu Y, Zhong G, et al. Compatibility of tanshinone IIA and astragaloside IV in attenuating hypoxia-induced cardiomyocytes injury. J Ethnopharmacol. 2017;204:67–76. doi:10.1016/j.jep.2017.03.053
   PubMed Web of Science ®Google Scholar
• Du N, Xu Z, Gao M, et al. Combination of ginsenoside Rg1 and astragaloside IV reduces oxidative stress and inhibits TGF-β1/Smads signaling cascade on renal fibrosis in rats with diabetic nephropathy. Drug Des Devel Ther. 2018;12:3517–3524. doi:10.2147/DDDT.S171286
   PubMed Web of Science ®Google Scholar